Key result
Irbesartan was at least equivalent to calcium channel blockers for antihypertensive efficacy but provided better renoprotective benefits in a pilot study of diabetic nephropathy.
Why the study?
Does renin-angiotensin system blockade reduce the progression of renal failure in patients with diabetes mellitus compared to calcium channel blockers or placebo?
Does renin-angiotensin system blockade reduce the progression of renal failure in patients with diabetes mellitus compared to calcium channel blockers or placebo?
Renin-angiotensin system blockade provides superior renoprotective benefits compared to calcium channel blockers in patients with diabetes mellitus, independent of blood pressure lowering.
No takes yet. Share an insight, caveat, or question.
May support irbesartan preference for renoprotection in diabetic nephropathy; hypothesis-generating, larger trials needed before practice change.
Luís M. Ruilope (1997) conducted a review in Diabetic nephropathy. Irbesartan vs. Amlodipine and placebo was evaluated on Progression of renal failure and antihypertensive efficacy. Irbesartan was at least equivalent to calcium channel blockers for antihypertensive efficacy but provided better renoprotective benefits in a pilot study of diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: